Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Danaher CorpDHR53.788.533.5129.957.98%4.19%42.64$256.01$812.3462,275$244.19

Detail of Danaher Corp

 
CEO
Mr. Rainer M. Blair
Employees
61000
Industry
Diagnostics & Research
Sector
Healthcare
Market cap
$180B

Company details

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$20.03B
Cost of goods (CoG)
-$8.09B
Gross profit (GP)
$11.94B
Operating expense (OE)
-$7.88B
Research and development (R&D)
-$1.38B
General and administrative (G&A)
-$6.50B
Operating income (OI)
$4.06B
Other income expense (OIE)
-$193.00M
Pretax income (PI)
$3.79B
Tax (TAX)
-$439.00M
Net income (NI)
$3.89B
Danaher Corp
DHR • XNYS • US
$244.19
+59.02 (31.89%)
Stock vs Industry average
  • Industry average

Dividend yield
0.43%
Trailing annual dividend rate
$1.05
Payout ratio
19.30%
EPS
$4.63
Margin profit
17.83%
52 week low
$192.979996
52 week high
$280.76001
50-day simple moving average
$255.05
200-day simple moving average
$256.01
Percent held by insiders
11.00%
Percent held by institutions
82.71%
Dividend yield
0.39%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
DHR +27.13%
eps change
DHR -26.14%